Navigation Links
FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder
Date:2/25/2011

PHILADELPHIA, Feb. 25, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration (FDA) granted full approval for PROMACTA® (eltrombopag), an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

PROMACTA initially received FDA orphan drug designation in May 2008 and accelerated approval in November 2008 for chronic ITP.  The FDA Accelerated Approval program offers a pathway to gain provisional marketing approval for therapies that address unmet patient needs.  Full approval of the therapy requires completion of post-marketing clinical trials and commitments that verify clinical benefit.

"Full approval of PROMACTA was based on clinical studies that provide physicians and patients with a broader understanding of its treatment effect and safety profile," said Steven Stein, MD, V.P. of Medicines Development, GlaxoSmithKline.  "PROMACTA is a testament to how the FDA Accelerated Approval Program supports development of therapies that meet unmet patient needs. Patients with limited treatment options gained access to PROMACTA while GSK conducted clinical studies that yielded additional efficacy and safety data."  

About Chronic ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding. There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.  People with chronic ITP often bleed from small blood vessels causing bruises or nosebleeds.

Updated Prescribing Information (PI)

The major changes in the Prescribing Inform
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Approach to Blood ... Pressure Management, ... in the discovery and development of novel small,molecule therapeutics, announced ... statistically significant,blood pressure reductions in a Phase 2a study in ...
... MDVN ) today announced that data from an ... antagonist, MDV3100, will be presented,in an oral presentation at ... in Chicago., Session title: New Targeted Strategies ... time: Monday, June 2 at 11:30 a.m. Central Time ...
Cached Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 "I ... beach because of her crutches," said an inventor from Wetumpka, ... the sights and sounds of the shore, I came up ... beach sand." , She created a prototype for the patent-pending ... The accessory enables the individual to use crutches, walkers, or ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... Gut Cure program was created by Karen Brimeyer, who wanted ... the world. , This guide is now easy to ... for instant download. In this guide, the author of the ... gut cure. , Daily Gossip writes in its review ...
(Date:8/30/2014)... August 28th, 2014: With the prevalence ... and the toll that takes on the individual as ... education for physical therapists addresses this problem. , In ... others, Hands-On Seminars is offering discounts on their continuing ... styles are available to fit the individual needs of ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2
... ... special section dedicated to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly ... in selling prescription glasses has been selling prescription sunglasses since ...
... appendicitis, but a patient,s symptoms are inconsistent with the ... or recurrent appendicitis and surgical treatment, according to a ... printed issue of the journal Radiology . ... results in missed appendicitis, with a possible increased risk ...
... medications should spur patient-doctor discussions, agency says, , TUESDAY, ... as Prevacid, Prilosec and Nexium will now carry a ... heightened risk for fractures, the U.S. Food and Drug ... consumers to use this class of medicines, called proton ...
... ... ... Shield of Massachusetts, Inc. (BCBSMA) and Northeast Health Systems Physician Hospital Organization, Inc. (NEPHO) ... marks the first North Shore physician group to adopt BCBSMA’s global payment model that is ...
... patient outcomes, researchers say , TUESDAY, May 25 (HealthDay ... obstructive pulmonary disease (COPD) do better when they receive ... patients who were given antibiotics early in their hospital ... less likely to have to be readmitted to the ...
... ... side-by-side this summer on extensive and collaborative research projects as part of Houghton College’s ... ... the Division of Math and Natural Science will work side-by-side this summer on extensive ...
Cached Medicine News:Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2Health News:Appendectomy may be best for patients with positive CT exam 2Health News:FDA Warns of Fracture Risk With Popular Heartburn Drugs 2Health News:FDA Warns of Fracture Risk With Popular Heartburn Drugs 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 3Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 2Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 3Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 4Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 5
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: